Clearwater Analytics Holdings, Inc.

Fundamentals7.0
Price Action6.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • Strong gross margins
  • Positive free cashflow
  • High valuation premium

AI
AI Summary

6.0

CWAN is fundamentally a high‑margin, cash‑generative SaaS whose investment case has shifted from pure growth upside to a deal‑and‑execution play—so prioritize monitoring integration milestones (Enfusion/Beacon/Bistro), net‑debt/EBITDA trajectory, and the $24.55 buyout litigation timeline because those three outcomes will determine whether the current market valuation is justified or vulnerable to a sharp rerating.

UnitEconomics
Legal
DealExecution‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

7.0

Key Financial Insights:

  • Strong gross margins
  • Positive free cashflow
  • High valuation premium

CWAN delivers strong gross margins and free cash flow but generates accounting net losses amid heavy R&D/opex and an intangible‑heavy balance sheet while trading at a very high EV/EBITDA multiple.

CashGenerative
HighValuation

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Tight range
  • Muted momentum
  • Near support/resistance

CWAN is trading in a tight, low-volatility range just above its last month SMA (~$23.36), with neutral momentum (RSI ~47) and immediate support near $23.14 versus resistance around $23.50–$23.54.

sideways
stalled
Support Level: $23.14
Resistance Level: $23.50–$23.54

Narrow band trading last month indicates unusually low short-term volatility

Sentiment & News

6.0

Key News Insights:

  • Legal probes
  • Activist stake
  • Derivative activity

Multiple law-firm probes, activist repositioning and unusual insider/derivative activity have intensified scrutiny of Clearwater's $24.55 buyout while the firm continues commercial wins like Orange Investment Advisors adopting its Enfusion platform.

shareholder
ClearingTech

Heightened litigation risk and investor repositioning could pressure deal terms and share price near-term, even as commercial traction supports long-term valuation